INTRODUCTION
In vertebrates, recognition of viruses by dendritic cells (DCs) and macrophages is critical to induce an activated state that stimulates innate and adaptive immune responses. Sensing of viruses by DCs and macrophages relies on the ability to recognize specific elements that are associated with the virus and absent from cells. A limited number of nucleic acid sensors have been identified (Vance, 2016) . The cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) is critical for the activation of DCs and macrophages via IRF3 in response to several DNA viruses and the lentivirus HIV (Gao et al., 2013; Lahaye et al., 2013) . In addition, cGAS appears to play a much broader role in response to a large number of microbes and self DNA (Chen et al., 2016) . The universal nature of this nucleic acid-based recognition raises the question of how DCs and macrophages achieve their high level of sensitivity while maintaining sufficient specificity in the recognition of viral infection. This suggests that additional mechanisms may exist to control cGAS-mediated sensing in the case of viral infection.
HIV-2 infects 1-2 million individuals (Visseaux et al., 2016) . The majority of HIV-2 infected individuals do not progress to AIDS, control viral replication, induce a potent immune response against the virus, and exhibit partial cross-protection against HIV-1 (Esbjö rnsson et al., 2012; Rowland-Jones and Whittle, 2007) . HIV-2 degrades the restriction factor SAMHD1 through its Vpx protein, leading to efficient viral DNA synthesis and innate immune activation in DCs through cGAS. In contrast, DCs neglect sensing of HIV-1 through cGAS because the virus does not degrade SAMHD1 (Sá ez-Cirió n and Manel, 2018) . Depletion of SAMHD1 using HIV-2/SIVmac Vpx protein sensitizes DCs for HIV-1 infection and restores innate immune activation in response to the virus (Manel et al., 2010) . Viral infection and recognition in DCs is thus likely one of several key processes that triggers protective immune responses during the course of HIV-2 infection. However, Vpx is simultaneously required for HIV-2/SIVmac viral replication in T cells (Shingai et al., 2015; Yu et al., 2013) , rendering the identification of other factors of innate sensing desirable.
HIV double-stranded DNA (dsDNA) plays an essential role in cGAS-mediated recognition (Herzner et al., 2015; Yoh et al., 2015) but it is not sufficient in DCs (Lahaye et al., 2013) . The viral capsid, which associates with viral dsDNA up to the nucleus interior (Chin et al., 2015; Peng et al., 2014) , has a critical role in enabling cGAS-mediated sensing of HIV dsDNA. The HIV-2 capsid is permissive to cGAS-mediated sensing during the early steps of infection, before the incoming viral DNA integrates. In contrast, the HIV-1 capsid evades sensing of the dsDNA before integration, even if Vpx is provided, and viral integration and expression of newly synthesized Gag protein is required to activate innate immunity. Capsid mutations alter HIV-1/2 DNA sensing by cGAS, implicating interactions with host factors (Lahaye et al., 2013; Manel et al., 2010; Rasaiyaah et al., 2013) . Cyclophilin A (CypA) binds to the HIV-1/2 capsid and modulates recognition of HIV-1/2 by DCs and macrophages, but the outcome of this interaction is virus strain-and cell-type-specific. These observations suggested the existence of a capsid-binding factor that would be essential for cGAS-mediated recognition of HIV-1/2.
RESULTS

NONO Directly Binds to HIV Capsid Protein
Given the physio-pathological differences between HIV-1 and HIV-2 infections, we reasoned that host factor(s) implicated in viral capsid recognition would preferentially bind to the HIV-2 capsid. We performed a yeast two-hybrid (Y2H) screen for protein fragments interacting with the HIV-2 capsid. NONO was identified with the best confidence score ( Figure S1A ). The NONO clones coded for fragments that all contained domain 256-310, representing the HIV-2 capsid-binding domain. Fulllength NONO interacted with full-length and N-terminal domain (NTD) of HIV-2 capsid and the NTD of HIV-1 capsid (Figures 1A, S1B, and S1C). We compared the strengths of the interaction with CypA as control. As predicted, the two capsids interacted with CypA, and the interaction with HIV-1 capsid was stronger than observed with HIV-2 capsid ( Figures 1A and S1C ). In contrast, the HIV-2 capsid interacted more strongly with NONO than the HIV-1 capsid. To determine direct proteinprotein interactions, we expressed and purified recombinant CypA, a NONO fragment that produces a soluble protein (domain 35-312) (Knott et al., 2016b) and capsid NTDs (Figure S1D) . Microscale thermophoresis (MST) confirmed a direct binding between NONO and the capsids NTD of HIV-1 or HIV-2. As expected in this assay (Lahaye et al., 2013) , the capsid NTD of HIV-1 binds to CypA while HIV-2 binding is below the detection limit ( Figure 1B) . In contrast, capsid NTD affinity of HIV-2 for NONO was higher than HIV-1 capsid NTD. Using MST, the full-length HIV-1 capsid bound NONO with the same affinity as the NTD (Figure S1E ), suggesting that the lack of detectable interaction of full-length capsid in yeast is not due to a reduced affinity ( Figure S1B ).
NONO Is Not Essential for HIV Infection
The conserved interaction of NONO with the HIV-1 and HIV-2 capsids suggested that it could be a host factor required for HIV infection. Depletion of NONO with CRISPR/Cas9 in THP-1 cells (Figures S2A and S2B) and U87 cells (Figures S2C and S2D) or with RNAi in THP-1 cells (Figures S2E and S2F) and HeLa cells (Figures S2G and S2H) had no major impact on HIV-1 and HIV-2 early phases of replication. To address late phases, we generated NONO-deficient HEK293FT cells, and this had no impact on viral production (Figure S2I ) and titer of viral progeny (Figures S2J and S2K) . While Vpx was encapsidated in HIV-2 particles as expected, NONO was not packaged in HIV-1 or HIV-2 particles ( Figure S2I ). Thus, NONO is not a general host-dependency factor of HIV infection.
NONO Is Essential in Dendritic Cells and Macrophages for Immune Activation after HIV Infection
These results raised the alternative possibility that NONO could be implicated in the recognition of HIV by the innate immune system. To determine if NONO was implicated in HIV recognition, we depleted NONO in monocyte-derived DCs (MDDCs), using Vpx and small hairpin RNA (shRNA) that induced intermediate (shRNA#1) or near complete (shRNA#5) depletion, and utilized a previously validated cGAS shRNA as a control (Figure 2A ). Similar to cGAS depletion, NONO depletion inhibited the expression of type I interferon (IFN), co-stimulatory molecule CD86, and inflammatory cytokine IP-10 (CXCL10) after infection by HIV-1 or HIV-2 GFP-reporter viruses . In contrast, NONO depletion did not impair DC activation by TLR3 agonist poly (I:C) or TLR7/8 agonist R848 (Figures 2D and S3C) . Activation by HIV-1 and HIV-2 capsid mutants that favor DC activation over infection was also dependent on NONO Figure 2 . NONO Is Essential for Immune Activation after HIV Infection in Dendritic Cells and Macrophages (A) Expression of NONO, cGAS, and actin in MDDCs at day 4, transduced at day 0 with a control shRNA against LacZ or individual shRNA against NONO or cGAS, combined with Vpx-containing VLPs (n = 7, one representative experiment is shown). (B) GFP and CD86 expression in MDDCs as in (A) and infected at day 4 for 48 hr with HIV-1 or HIV-2 GFP-reporter viruses (n = 7, one representative experiment is shown). The shRNA transduction at day 0 includes Vpx, which abrogates the SAMHD1 restriction for HIV-1 at day 4. (C) Dose-response expression of GFP and CD86 as in (B) (n = 7, paired repeated measure [RM] ANOVA). Virus inoculum volume is indicated. expression, while activation by the cGAS agonist HT-DNA, or the cGAS product and stimulator of interferon genes (STING) agonist cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), was not affected by NONO depletion (Figure S3D ). Dose-titrations on multiple donors confirmed that the response to HIV required NONO expression, but not the response to cGAMP or HT-DNA ( Figure S3D ). Accordingly, NONO depletion did not inhibit cGAS messenger or protein expression ( Figures  2A and S3E ). Viral infection, monitored by GFP reporter expression, was not affected by NONO or cGAS depletion in MDDCs ( Figures 2B, 2C , and S3B). The amount of reverse-transcribed DNA, nuclear HIV DNA, and integrated HIV were also not affected by NONO depletion, indicating that the lack of DC activation was not due to a limiting dose of DNA ( Figure S3F ). To confirm production of antiviral interferons, we measured the production of type I and type III IFN. IFN-b was induced by HIV-2 infection in a NONO-dependent manner ( Figure S3G ), while it was below the detection limit for HIV-1. We found that MDDCs secreted high levels of IFN-l1, a type III IFN previously reported to be co-expressed with type I IFN in response to viral infection (Odendall et al., 2014 ) ( Figure S3H ). IFN-l1 induction by HIV-1 and HIV-2 infection required NONO, but not its induction by cGAMP ( Figure S3H ). The induction of the IFN-stimulated gene (ISG) SIGLEC1 was also inhibited by NONO depletion after infection of DCs with a replication-competent HIV-1 ( Figure S3I ). Type I and III interferons are IRF3 target genes and HIV recognition in DCs through cGAS leads to IRF3 phosphorylation and requires IRF3. IRF3 phosphorylation in response to HIV-1 or HIV-2 infection was abrogated in cells depleted for NONO (Figure 2E) . The total level of IRF3 was not altered. Phosphorylation of IRF3 after transfection of cGAMP, the product of cGAS, was not altered in NONO-depleted DCs. Thus, NONO is required for IRF3 activation in DCs in response to HIV, and does not appear to play a general role in IRF3 activation through the cGAMP-STING pathway. To validate the role of NONO in primary cells, we purified primary cDC2 (CD1c + DCs) from human blood and depleted NONO and cGAS using lentiviral vectors (Figure S3J) (Silvin et al., 2017) . HIV-1 or HIV-2 infection induced CD86 expression in cDC2, and this was inhibited in the absence of cGAS or NONO ( Figures 2F, 2G , and S3K). The rate of viral infection was not significantly altered by the absence of cGAS or NONO (Figures 2F, 2G, and S3K) .
Similar to DCs, HIV-1 can activate cGAS in monocyte-derived macrophages in the presence of Vpx (Gao et al., 2013) . NONO depletion in macrophages did not significantly alter the rate of infection with HIV-1 or HIV-2 ( Figure 2H ). However, the induction of IP-10 protein was inhibited by NONO depletion in response to HIV-1 or HIV-2, but not in response to cGAMP or HT-DNA ( Figure 2I ). The expression of the ISGs IFIT1, MX1, and OAS1 was also inhibited by NONO depletion in response to infection, but not to stimulation with synthetic agonists ( Figure 2J ).
HIV Capsid Reaches the Nucleus of Dendritic Cells and
Interacts with NONO NONO is a pan-nuclear protein in DCs ( Figure S4A ). We thus tested if the incoming HIV-2 capsid protein localized to the nucleus of DCs. Using a staining protocol optimized for nuclear capsid detection (Chin et al., 2015) and integrase inhibitor to restrict detection to incoming viral capsids, we found that the incoming HIV-2 capsid reaches the interior of the nucleus upon infection at MOI of 2 (Figures 3A, 3B, and S4B). Nuclear/cytoplasmic fractionation analyses confirmed this finding and further showed that newly synthesized GAG can also be found in the DC nuclear fraction (Figures 3C and S4C) . Immuno-electron microscopy also identified incoming nuclear capsid as intranuclear structures stained by anti-capsid antibody (Figures 3D and S4D) . Their dimensions were consistent with the shape of viral cores (Figures 3D and S4D) but reduced compared to mature core of extracellular particles ( Figure S4E ) (Briggs et al., 2003) . Proximity-ligation assay (PLA) also identified nuclear capsid, with an average of 11 foci per cell (Figures 3E and 3F) . To exclude that nuclear capsid was newly expressed Gag due to leakiness of the integrase inhibitor, we infected DCs with HIV-2 deleted for Gag (DGag) complemented with encapsidation-signal deficient HIV-2 (DJ). As expected, Gag was not expressed in DCs infected with HIV-2 DGag (Figure 3G, DJ+DGag) . Similar to HIV-2, HIV-2 DGag induced CD86, IP-10, and IFN in dendritic cells in the absence of integration and in a cGAS-and NONOdependent manner ( Figure 3H ). The incoming capsid for HIV-2 DGag viruses was also found in the nucleus ( Figure 3I ). To test if the incoming viral capsid could interact with NONO in the nucleus, we performed double-labeled immuno-electron microscopy. Nuclear structures positive for capsid were also positive for NONO ( Figure 3J ). We analyzed 157 CA-positive nuclear structure and 60% contained at least one NONO gold particle ( Figure 3K ). The double-labeled structures were also observed on two sequential sections ( Figure S4F ). In contrast, NONO was not detected on the capsid from enveloped viral particles released by infected macrophages ( Figure S4G ). Altogether, (D) IP-10 production by MDDCs transduced as in (A) and infected with HIV-1 or HIV-2 GFP-reporter viruses (33 mL) or treated with poly(I:C) (1.33 mg/mL) or R848 (0.33 mg/mL) for 48 hr (n = 7, paired RM ANOVA on log-transformed data). (E) Western blot of phospho-Ser396-IRF3 in MDDCs transduced as in (A) and infected 16 hr with HIV-1 or HIV-2 GFP-reporter viruses or transfected 12 hr with cGAMP (1.33 mg/mL) (n = 3, one representative experiment is shown). (F) GFP and CD86 expression in cDC2 transduced and infected as in (B) (n = 5, one representative experiment is shown). (G) Expression of GFP and CD86 as in (F) (n = 3, paired RM ANOVA, virus inoculum: 33 mL). (H) GFP and SIGLEC1 expression in macrophages transduced and infected at day 9 as in (B) or treated with cGAMP (1.33 mg/mL) or HT-DNA (1.66 mg/mL) (n = 4, paired RM ANOVA). (I) IP-10 production by macrophages as in (H) (n = 4, paired RM ANOVA on log-transformed data). we conclude that the incoming HIV-2 capsid reaches the nucleus and directly associates with NONO.
NONO Is Required for the Presence of cGAS in the Nucleus These results raised the possibility that NONO could regulate cGAS localization in cells. While cGAS was initially reported to localize mainly in the cytosol , cGAS expressed in interphase can access the nuclear compartment as a result of nuclear envelope rupture or mitosis (Denais et al., 2016; Mackenzie et al., 2017; Raab et al., 2016; Yang et al., 2017) , and cGAS was detected in the nucleus of human primary fibroblasts (Orzalli et al., 2015) . Using nuclear/cytoplasmic fractionation, we found that endogenous cGAS was present in both the nucleus and the cytosol in monocyte-derived DCs (MDDCs), macrophages (MDMs), THP-1, and HeLa cells ( Figure 4A ). NONO was found in the nucleus, and STING was detected only in the cytoplasm.
Calnexin was detected only in the cytoplasmic fraction of DCs and macrophages, thus excluding a contamination of nuclear fractions with endoplasmic reticulum. The presence of cGAS in the nucleus raised the question of how cGAS is prevented from massive activation by nuclear DNA. Using an in vitro enzymatic assay for cGAS activity, we found that cGAS is not activated by nucleosomes ( Figures 4B and 4C ). Extracting DNA from nucleosomes rescued cGAS enzymatic activity similarly to naked DNA. Spiking naked DNA into nucleosomes also rescued cGAS enzymatic activity, excluding a dominant-negative effect ( Figure S4H ). Thus, the nucleosomal state of nuclear DNA limits cGAS activation. We next tested the role of NONO on cGAS localization in DCs. Upon NONO depletion, the baseline level of nuclear cGAS was reduced, while the cytoplasmic cGAS level was not affected ( Figures 4D, 4E , S4I, and S4J). The expression of cGAS was increased in control cells treated with HIV-1 or cGAMP, in agreement with the production of IFN, because cGAS is an ISG (Schoggins et al., 2011) . Of note, we also detected the presence of unprocessed Gag protein of HIV-1 and HIV-2 in the nucleus of DCs ( Figures 4D and S4I ). These results suggested that NONO could interact with cGAS. Using co-immunoprecipitation, both NONO and cGAS pulled down each other ( Figures 4F and 4G ). The cGAS-NONO interaction was resistant to benzonase, supporting putative proteinprotein interactions ( Figures 4H and S4K ). To visualize the localization of cGAS as a function of NONO, we quantified cGAS intensity by immunofluorescence microscopy in control or . The level of nuclear cGAS was linearly correlated with the level of nuclear NONO in DCs treated with a NONO shRNA. In control cells, the level of nuclear cGAS was correlated in the fraction of cells expressing lower levels of NONO ( Figure S4L ). In contrast, the level of cytosolic cGAS was not correlated with NONO. We conclude that NONO forms a complex with cGAS in the nucleus and that it is required for the presence of cGAS in the nucleus, but has no impact on the cytosolic pool of cGAS.
NONO Is Required for cGAS-Mediated Sensing of HIV DNA These results suggested that NONO could have a direct role in cGAS-mediated sensing of HIV DNA. cGAMP production by cGAS results in phosphorylation of STING at Serine 366. HIV-2 infection induced phosphorylation of STING in DCs, and this was inhibited by depletion of cGAS or NONO ( Figure 5A ). Depletion of NONO or cGAS had no impact on STING phosphorylation in response to cGAMP. Next, we immunoprecipitated cGAS with a chromatin immunoprecipitation (ChIP) protocol to determine the role of NONO in the association of HIV-2 DNA with cGAS in the nucleus ( Figure 5B ). HIV-2 DNA was associated with cGAS in control infected cells, and this was reduced by 21-fold in NONO-depleted cells ( Figure 5C ). Altogether, these data show that NONO is required for cGAS recognition of HIV-2 DNA and STING activation.
NONO Recognizes a Site of Genetic Fragility in HIV Capsids
These data suggested that NONO is a HIV capsid recognition receptor of innate immunity. Considering that virus recognition by the innate immune system is critical for inducing antiviral responses, it was intriguing that HIV capsid recognition by NONO would be based on protein-protein interactions, which are presumably sensitive to escape mutations. However, the HIV capsid is considered a genetically fragile structure, which poorly tolerates mutational changes (Rihn et al., 2013) . To test if NONO recognized a site of genetic fragility in the capsid protein, we mapped single amino acids essential for NONO binding to capsid ( Figure S5A ). We found that D101 and I102 were essential for NONO binding to HIV-2 capsid, while Y49 had a partial role ( Figures 6A and S5B ). D101 and I102 are conserved in HIV-1 capsid, while Y49 is Q50 in HIV-1 ( Figure 6B ). These residues are surface-exposed and closely located in space, (G) Detection of GAG, CA, and actin. MDDCs were infected 24 hr in presence or not of RAL or AZT, with HIV-2 (HIV-2 WT), HIV-2 DJ, or HIV-2 DJ+DGag (n = 2, one representative experiment is shown). (H) GFP, CD86 expression, and IP-10, IFN-l1 production by MDDCs transduced at day 0 with a control shRNA against LacZ or shRNAs against cGAS or NONO and subsequently infected 48 hr at day 4 as in (G) or treated with cGAMP (1.33 mg/mL) for 48 hr (n = 4, paired RM ANOVA, ****p < 0.0001, ns, not statistically significant, on log-transformed data for IP-10 and IFN-l1 production). (legend continued on next page) consistent with a protein-binding interface ( Figure 6C ). We produced viruses with mutations D101A and I102A in HIV-2, and the corresponding D103A and I104A in HIV-1. The mutant viruses showed a 3-and 2-log reductions in viral titers, respectively ( Figure 6D ). In producer cells, HIV-2 D101A and I102A showed normal levels of cell-associated Gag but reduced levels of cell-associated CA, and HIV-1 D103A and I104A showed reduced levels of cell-associated Gag and CA ( Figure S5C ).
Extracellular viral proteins were reduced for HIV-1 and HIV-2 mutants ( Figure S5C ). HIV-1 and HIV-2 do not normally package NONO in viral particles during viral production ( Figure S5D ), indicating that the reduced viral titer was not due to a loss of NONO binding during viral production. The reduction in viral titers was not due either to gaining a dependency on cyclophilin A inhibition ( Figure 6D ). Electron microscopy showed that one defect of HIV-1 I104A was the accumulation beneath the plasma membrane of virus-producing cells and a failure to bud ( Figure 6E ).
These results indicate that HIV-1 D103A, I104A, and HIV-2 D101A and I102A are severely defective. We next tested if a moderate polymorphic exchange could be tolerated. We generated HIV-2 Y49Q and its counterpart HIV-1 Q50Y. While Y49Q diminished the interaction with NONO for HIV-2 capsid, Q50Y increased it for HIV-1 capsid ( Figure 6F ). The interactions with CypA were not altered by the mutations ( Figure S5E ). Gag expression, budding, and capsid maturation in the particles was normal ( Figure S5F ). However, HIV-1 Q50Y and HIV-2 Y49Q showed 1-and 2-log decreases in viral titers, respectively ( Figure 6G ). To establish a causal link between NONO recognition and sensing, we examined the activation of DCs in response to infection by capsid mutants. HIV-1 D103A, I104A and HIV-2 D101A, I102A were too defective to be tested in this assay. We infected DCs with capsid-normalized amount of HIV-1 Q50Y, HIV-2 Y49Q, and wild-type (WT) viruses. HIV-1 Q50Y showed a profound defect in viral integration and GFP expression ( Figures  S5G and S5H ), which prevented further analysis because immune activation by HIV-1 in DCs with Vpx requires integration and Gag expression (Manel et al., 2010) . HIV-2 Y49Q was also profoundly defective for integration and GFP expression, independently of NONO ( Figures 6H and 6I ). HIV-2 Y49Q produced 10-fold less viral DNA than its WT counterpart per unit of capsid ( Figure 6I ). HIV-2 WT readily induced IFN-l1 in a NONO-dependent manner ( Figures 6H and 6J ). At comparable levels of input capsid, induction of IFN-l1 by HIV-2 Y49Q was 26-fold less than WT ( Figures 6H and 6J ). At comparable levels of viral DNA, residual induction by HIV-2 Y49Q was also independent of NONO, and 2-fold less than WT ( Figures 6H and 6J) . These results raised the question of the conservation of the NONOcapsid interaction. Using Y2H, we find that NONO binding is conserved in SIVmac and SIVsmm capsids ( Figures S6A-S6C ). D101 and I102 are conserved throughout the primate lentiviruses ( Figure 6K ). Residue Y49 is highly conserved throughout the primate lentiviruses, while the HIV-1 group M and SIVcpz lineages (E) Quantification of the densitometric values from nuclear NONO and cytosolic or nuclear cGAS after cytoplasmic and nuclear fractionation in MDDCs as in (D) . Cytosol ratio was calculated over tubulin, nuclear ratios were calculated by over histone H3 (solid lines) or lamin B1 (dash lines) (n = 9; paired RM ANOVA). (F) Pull-down of NONO by cGAS. 293FT cells were co-transfected with indicated plasmids and processed for anti-FLAG immunoprecipitation (IP) and western blot (n = 3, one representative experiment is shown). (G) Pull-down of cGAS by NONO. 293FT cells were co-transfected with indicated plasmids and processed for anti-HA immunoprecipitation and western blot (n = 3, one representative experiment is shown). (H) Pull-down of NONO by cGAS is resistant to nucleic acid digestion. 293FT cells were co-transfected with indicated plasmids and processed for anti-FLAG immunoprecipitation with or not benzonase treatment and western blot (n = 3, one representative experiment is shown). (legend continued on next page) mainly encode Q50 ( Figure 6K ). NONO is also highly conserved in vertebrates and primates and has evolved under purifying selection ( Figures S6D-S6F ). Using Y2H mapping, we found that I275 and E278 residues in NONO, which are aligned in space (Passon et al., 2012) , are essential for interaction with HIV-2 capsid and conserved in primate NONO proteins, except in tarsier ( Figures S6G-S6I ), in agreement with recognition of a conserved molecular pattern by NONO and the evolution of several innate immune sensors (Quintana-Murci and Clark, 2013) . We conclude that NONO recognizes a conserved interface in HIV capsid, which cannot tolerate the escape mutations tested as these produce a profound fitness cost, consistent with genetic fragility.
Genetic Validation Using Dendritic Cells of NONO-Deficient Patients
Genetic validation is critical for the identification of pattern recognition receptors (Vance, 2016) . Loss-of-functions mutations in NONO have been reported in patients with cognitive disabilities (Mircsof et al., 2015) . We obtained PBMCs from 2 independent patients and generated monocyte-derived DCs. We confirmed the lack of expression of NONO in mononuclear cells ( Figure 7A ). DCs deficient for NONO showed a profound reduction in their ability to produce IP-10 and IFN-l1 after infection by HIV-1 with Vpx or HIV-2, but not after HT-DNA or cGAMP treatments ( Figures 7B, S7A , and S7B). A dose-response analysis confirmed that the unaltered response to cGAMP was not due to saturation ( Figure S7B ). The rate of HIV-1 and HIV-2 infection was also not affected by NONO deficiency. Expression of the ISGs MX1, IFIT-1, OAS1, and CXCL10 was also reduced by NONO deficiency in response to infection ( Figure 7C ). Using whole-genome gene expression analysis, 123 genes were significantly upregulated by HIV-2, and 52 were previously recognized ISGs ( Figures 7D and 7E ). 93% of the upregulated genes were dampened in NONO-deficient cells after HIV-2 infection. A similar pattern was observed in DCs infected by HIV-1 with Vpx, but gene induction in WT cells was reduced for HIV-1 with Vpx as compared to HIV-2. The genes were not expressed at a lower baseline in the uninfected NONO-deficient sample. For one NONO-deficient patient, we also stimulated cells with cGAMP ( Figures 7F and 7G ). Unlike HIV-2, there was no difference between WT and knockout (KO) for cGAMP stimulation, thus excluding global dysregulations in NONO KO cells.
DISCUSSION
NONO fits the criteria for an HIV capsid sensor essential for innate immune activation of DCs and macrophages. We pro-pose that NONO is required for the presence of cGAS in the nucleus, and that the chromatin state limits cGAS activation by self DNA; upon nuclear entry of HIV-2, the viral capsid is recognized by NONO, leading to recruitment of HIV-2 DNA in the vicinity of cGAS ( Figure 7H ). NONO was previously detected within protein complexes associated with HIV complexes or HIV-related host factors, but the nature and significance of these associations remained unresolved (Milev et al., 2012; St Gelais et al., 2015) . NONO is a multifunctional RNAand DNA-binding protein scaffold implicated in transcription, splicing, DNA damage response, circadian rhythm, and neuronal development (Knott et al., 2016a) . NONO localizes to the nucleoplasm and can also participate to the formation of nuclear paraspeckles. Paraspeckles are intranuclear bodies that require the lncRNA NEAT1 for assembly (Fox et al., 2018) . At least three findings argue against a role for paraspeckles in NONO recognition of HIV. First, NONO staining is pan-nuclear in DCs with no obvious nuclear bodies. Second, the NONO-cGAS complex was resistant to nuclease treatment. Third, NEAT1 was expressed at very low level in DCs in our gene expression analysis and this was unaltered by the stimulations. Although we did not observe a general dysregulation in immune activation in NONO-deficient cells, we do not discard the possibility that NONO or paraspeckles could play immuno-regulatory roles beyond HIV recognition, perhaps in relation to other functions of nuclear cGAS to be uncovered. STING and NONO localizations were mutually exclusive in DCs, macrophages, and THP-1, and STING expression was comparatively undetected in HeLa cells, in agreement with studies that did not detect a biologically active IFN response in response to transfected DNA in these cells (Gentili et al., 2015; Lau et al., 2015; Rasaiyaah et al., 2013) . In contrast, NONO was found in HeLa cells to co-sediment with a ribonuclear complex that contained cGAS and STING and that could regulate the expression of IFN in response to transfection of a synthetic dsDNA oligonucleotide (Morchikh et al., 2017) . These discrepancies warrant further studies.
We find cGAS to be present in the nucleus of DCs, macrophages and two cell lines at steady state. DCs arise from precursors with high proliferative potential (Lee et al., 2015) . cGAS can enter the nucleus during each of the previous mitoses that took place in the DC precursors. Transient nuclear envelope ruptures also occur physiologically during migration of non-cycling DCs in tissues (Raab et al., 2016) . Other factors could play an active role in the nuclear import of cGAS. In DCs, we find that NONO is essential for the presence of cGAS in the nucleus. This may be leveraged in future work to identify nuclear functions of cGAS beside HIV recognition. (I) Quantification of late RT, 2LTR circles, and integrated viral cDNA products 24 hr after infection of LacZ cells as in (H) , in presence RAL or AZT with 10 mM nevirapine (NVP) (= RTi) when indicated (n = 4; paired RM ANOVA on log-transformed data). (J) IFN-l1 production in MDDCs transduced and infected as in (H) and treated as in (I) . Comparable levels of input capsid and viral DNA between HIV-2 WT and Y49Q are indicated by a red or blue square, respectively (n = 4; paired RM ANOVA on log-transformed data). (K) Phylogenetic analysis of primate lentiviruses (gag, n = 202 sequences). The clades that include HIV-1 and HIV-2 strains are highlighted in dark blue and red, respectively. Logos (from 9,290 HIV/SIV sequences) show the amino acids corresponding to those involved in the NONO-HIV CA interaction (seq, sequences; positions 49, 101, and 102 are highlighted: residues identical to HIV-2 are in orange, while Q50 in HIV-1 group M and SIVcpz is highlighted in light blue). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not statistically significant; bars and lines indicate mean ± SEM. See also Figures S5 and S6. (legend continued on next page)
We find that the HIV-2 capsid has increased affinity for NONO as compared to HIV-1, which is consistent with the reduced pathogenicity and better immune control of HIV-2 over HIV-1. HIV-2 contains Vpx and its capsid efficiently binds NONO, enabling recognition of the incoming virus. HIV-1 recognition with Vpx requires viral integration and expression, and we find accumulation of newly synthesized HIV-1 Gag in the nucleus of DCs. The existence of small nuclear pool of HIV-1 Gag has previously been described, but its function and conformation is not known (Grewe et al., 2012) . New viral DNA synthesis after HIV-1 Gag expression and cleavage of newly expressed Gag is not required for sensing in dendritic cells (Gao et al., 2013; Manel et al., 2010; Sunseri et al., 2011) . Thus, while newly expressed Gag is not expected to interact with viral DNA in cis, it may interact in trans with incoming capsid-DNA complexes through NONO in the nucleus. NONO forms multimers in the nucleus (Knott et al., 2016a) , which could connect newly synthesized Gag to incoming capsid-DNA complexes. Furthermore, we find that the gene signature induced by HIV-1 with Vpx is dampened as compared to HIV-2, and that HIV-2 induces higher levels of IFN-I, IFN-III, and CD86 than HIV-1, even if Vpx is provided. Consistent with this, in macrophages, the level of ISG induction was similar for HIV-2 and HIV-1 with Vpx, despite a lower rate of infection for HIV-2. Levels of IP-10 protein were comparable between HIV-2 and HIV-1 with Vpx, possibly related to post-transcriptional regulation (Casrouge et al., 2011) . There was also lower level of phospho-IRF3 for HIV-2 than HIV-1 with Vpx at the time point tested. This experiment was not designed to compare the magnitude of phospho-IRF3 between stimuli, but it suggests that the dynamic of IRF3 phosphorylation may be different between the two viruses. We conclude that the decreased affinity of HIV-1 capsid for NONO as compared to HIV-2 contributes to a reduced magnitude of innate immune activation, even if Vpx is provided to HIV-1.
We show that NONO directly associates with HIV-2 capsids in the nucleus. It is currently thought capsid is co-imported with the viral DNA in the nucleus. We speculate that other active import mechanisms of capsid and/or Gag in the nucleus could also take place.
NONO recognizes a surface on HIV capsids that appears to have a limited ability to tolerate mutations. Supporting this notion, this region was recently implicated in the regulation of dynamic pores in the HIV capsid that are critical for virus viability and thus likely highly sensitive to mutations (Jacques et al., 2016) . Furthermore, HIV-1 D103, I104, and Q50 are located within CTL epitopes that have been associated with control of viral replication, consistent with a fitness cost of mutating them (Honeyborne et al., 2007; Migueles et al., 2014) .
The nucleus is generally considered to be a protection for host cell DNA, and viruses in turn have evolved a number of capsid-based strategies to bring their nucleic acids into the nucleus (Ravindran and Tsai, 2016) . Viral capsids are accordingly typical molecular patterns found mainly in viruses, and capsid assembly and functions are under strong structural constrains, likely underlying their genetic fragility. Recognition of viral capsid proteins by host proteins, particularly at sites of genetic fragility in capsids, could be an evolutionary favorable mechanism to ensure host protection against viruses that are able to evolve rapidly. A twostep mechanism of viral recognition involving both viral nucleic acids and viral capsid proteins may also represent a general mechanism to maximize specific and sensitive discrimination of viruses over related self-elements. Our work enables exploring viral capsid-based recognition and NONO-cGAS crosstalk in the design of vaccine and therapeutic strategies.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (Mircsof et al., 2015) .
Cells lines
For others experimental models, different cell lines were used, female cell lines as GHOST (GHOST X4R5), 293FT and HeLa cells and male cell lines as HL116, THP-1 and U87 cells. As described on the Key Resources Table, 293FT, U87, THP-1 and GHOST X4R5 were commercial cell lines from NIH AIDS Reagent Program, ATCC or Thermo Fisher Scientific. Cell lines validation were performed by STR and POWERPLEX 16HS analysis for 293FT and HeLa cell lines.
METHOD DETAILS
Constructs
The HIV-1 GFP-reporter virus was NL4-3 DvifDvprDvpuDenvDnef encoding GFP in nef; the HIV-1 replication-competent GFP-reporter virus was NL4-3 with BAL env and GFP in nef (R5-GFP); the HIV-2 GFP-reporter virus was ROD9 DenvDnef encoding GFP in nef (Manel et al., 2010) . HIV-1 V86I-IAP91LPA-M96L (HIVac-1) and HIV-2 P86HA (HIVac-2) were previously described (Lahaye et al., 2016) . HIV-1 D103A, HIV-1 I104A, HIV-1 DI104AA, HIV-1 Q50Y, HIV-2 DJ, HIV-2 DGag, HIV-2 D101A, HIV-2 I102A, HIV-2 DI102AA and HIV-2 Y49Q were generated by overlapping PCR mutagenesis. Corresponding mutagenized sequences are listed in Table S1 . CMV-VSVG, psPAX2, pLKO1puro, pSIV3+, were previously reported (Manel et al., 2010) . pNL(AD8) was previously reported (Berre et al., 2013) . pLentiCRISPRv2 (Addgene #52961) (Sanjana et al., 2014) , pX458 (Addgene #48138) (Ran et al., 2013) , gRNA_Cloning Vector (Addgene #41824) (Mali et al., 2013) were used. shRNA against LacZ, TNPO3, cGAS, NONO were in the pLKO1puro vector and are listed in Table S3 . gRNA against NONO were in the pLentiCRISPRv2 or in the gRNA_Cloning Vector and are listed in Table S4 . In all final constructs, the entire DNA fragments originating from the PCR or synthesis and encompassing the restriction sites used for cloning were fully verified by sequencing. Plasmid DNA was purified using with the low endotoxin HiPure plasmid kit (Thermo Fisher Scientific). Recombinant plasmid DNA did not induce dendritic cell maturation, and viral-producing cells were washed after DNA transfection.
Cells
GHOST (GHOST X4R5), 293FT and HeLa cells were cultured in DMEM, 10% fetal bovine serum (FBS) (Corning), Penicillin-Streptomycin (GIBCO). THP-1 cells were cultured in RPMI medium, 10% FBS (Corning), Penicillin-Streptomycin (GIBCO) and THP-1 cells are differentiated with 30 ng/ml (50 nM) of PMA for 16hrs. U87 cells were cultured in MEM, 10% fetal bovine serum (FBS) (GIBCO), Penicillin-Streptomycin (GIBCO). Human peripheral blood mononuclear (PBMCs) cells were isolated from buffy coats from normal human donors (approved by the Institut National de la Santé et de la Recherche Mé dicale ethics committee) using Ficoll-Paque PLUS (GE). CD14 + cells were isolated by a positive selection with anti-human CD14 magnetic beads (Miltenyi) from PBMCs. Purity was checked by flow cytometry using an anti-CD14 antibody (listed in KEY RESOURCES TABLE) and purity was superior to 99%. To obtained dendritic cells (MDDCs), CD14 + cells were cultured in RPMI medium, 10% FBS (Eurobio), Penicillin-Streptomycin, Gentamicin (50 mg/ml, GIBCO) and HEPES (GIBCO) in the presence of recombinant human GM-CSF (Miltenyi) at 10 ng/ml and IL-4 (Miltenyi) at 50 ng/ml. Fresh media was added at day 3, and cells were stimulated or infected at day 4. To obtained macrophages (MDMs), CD14 + cells were cultured in RPMI medium, 5% FBS (Eurobio), 5% human serum (Sigma), Penicillin-Streptomycin, Gentamicin (50 mg/ml, GIBCO) and HEPES (GIBCO) in the presence of recombinant human M-CSF (Miltenyi) at 50 ng/ml. Fresh media was added at day 5 or 6, and cells were stimulated or infected at day 9. cDC2 were isolated thought this protocol. Total blood DCs from PBMCs were enriched with EasySep human pan-DC pre-enrichment kit (StemCell Technologies). DC enriched fraction were stained with antibodies against HLA-DR-APCCy7, CD123-APC, CD11c-PECy7, CD1c-PCP5.5, CD141-Vioblue and with cocktail antibodies against lineage markers CD19, CD3, CD14 and CD16 in channel FITC. cDC2 were sorted as Lin-HLADR+ CD11c+ CD123-CD1c+ CD141-. All cells were sorted on a FACSAria (BD) using Diva software (BD) in 5ml polypropylene round-bottom tubes containing 1mL X-VIVO-15 media (BE04-418F; Lonza). Post-sort cell purity after gating on live cells by FCS/SSC was routinely between 96 and 99%. For lentiviral infections of sorted DCs, cells were cultured in X-VIVO-15 (BE04-418F; Lonza) complemented with recombinant human GM-CSF at 3ng/ml and Penicillin/Streptomycin.
Virus production
Viral particles were produced by transfection of 293FT cells in 6-well plates with 3 mg DNA and 8 mL TransIT-293 (Mirus Bio) per well; for VSV-G pseudotyped SIVmac VLPs, 0.4 mg CMV-VSVG and 2.6 mg pSIV3 + ; for HIV-1 and HIV-2 GFP-reporter viruses, 0.4 mg CMV-VSVG and 2.6 mg HIV or SIV DNA; for HIV-1 replication-competent GFP-reporter virus, 3 mg of R5-GFP or 3 mg of pNL(AD8); for shRNA vectors, 0.4 mg CMV-VSVG, 1 mg psPAX2 and 1.6 mg pLKO1puro-derived shRNA; for gRNA vectors, 0.4 mg CMV-VSVG, 1 mg psPAX2 and 1.6 mg pLentiCRISPRv2-derived gRNA. One day after transfection, media was removed, cells were washed out once and fresh media was added. Viral supernatants were harvested one day later, filtered at 0.45 mM, used fresh or aliquoted and frozen at À80 C. Viral titers were measured on GHOST cells titration as previously described (Manel et al., 2010) or by HIV-1 p24 ELISA (XpressBio), HIV-2 p26 values are based on an HIV-1 p24 standard in the ELISA and should thus be considered as relative values. Elisa absorbance acquisitions were acquired on a FLUOstar OPTIMA (BMG Labtech) and data were analyzed and exported to Excel with MARS Data Analysis Software (BMG Labtech). Viral supernatants did not induce dendritic cell activation in the absence infection.
Infections
At day 4 of MDDC differentiation, cells were harvested, counted and resuspended in fresh media at a concentration of 1 to 0.5 million per ml with 1mg/ml protamine, GM-CSF and IL-4, and 100 mL was aliquoted in round-bottomed 96-well plates. For infection, 50 ml of media or SIVmac VLPs (refered to as Vpx) were first added (if necessary). One-hundred microliters of media or dilutions of viral supernatants. 48 hours after infection, cell culture supernatants were harvested and ultraviolet-irradiated to inactivate free virus. Supernatants were subsequently used for IP-10 quantification or IFN quantification. Cell-surface staining of CD86 (eBioscience) or SIGLEC1 (Miltenyi Biotec) were also performed 48 h after exposure and analyzed on a BD Accuri C6 or a BD FACSVerse flow cytometer. Stimulation and DCs activation were positively controlled by treatment with high molecular weight poly(I:C) (Invivogen), R848 (Invivogen) directly added in the media, or with HT-DNA (Sigma), cGAMP (Invivogen) delivered with Lipofectamine 2000 (Thermo Fisher Scientific) transfection. Monocyte-derived macrophages were infected by NL(AD8) as previously described (Berre et al., 2013) .
Knock-down by shRNA interference
For knock-down experiments, fresh monocytes, THP-1 or HeLa cells were transduced with shRNA vectors as previously described (Manel et al., 2010) . Knock-down efficiency was measured by western blotting at day 4 (for MDDCs at the time of infection), at day 9 (for MDMs at the time of infection) or between day 8-10 for the other cells. Puromycin was added at day 2 (2 mg/ml). At day 4 for DCs or at day 9 for MDMs, cells were harvested, counted, seeded at 0.5 million per ml in 96-well U bottom plate as described above and infected or stimulated in 200 ml of final volume. Surface CD86 or SIGLEC1 expression and soluble IP-10 or IFN production were measured at day 48 hours after treatment. For infection with HIV-1 replication-competent GFP-reporter virus, the cells were spinoculated at 1200 g for 2 hours at 25 C. THP-1 knock-down cells were seeded at 0.5 million per ml in 96-well flat bottom plate in 200 ml of final volume treated or not with PMA (30 ng/ml) for 16 hours. THP-1 media was changed by 100 mL of fresh media and infected by 100 mL of media or dilutions of viral supernatants (with 1mg/ml protamine). GFP expression was measured 48h post-infection. HeLa cells were harvested, counted, seeded and infected as previously described for GHOST cells (Manel et al., 2010) . Sorted cDC2 were resuspended at 0.5 million cells per mL in X-VIVO-15 and 100mL was added per well in U bottom 96-well plates. cDC2 were transduced with 100 ml of LacZ shRNA, cGAS shRNA or NONO shRNA lentivectors after sorting in presence of 50 ml of SIV-VLP (G) . Puromycin was added at day 2 (2 mg/ml). At day 4, cDC2 were washed and 100ml of fresh media was added and infected in presence of 1mg/ml protamine. 50,000 cells were used for RNA extraction with NucleoSpin RNA (Macherey-Nagel) and cGAS expression was analyzed by RT-qPCR as described below. At day 6, surface CD86 and GFP expression were measured by flow cytometry.
Knock-out by gRNA interference
For knock-out experiments, THP-1 or U87 cells were transduced with pLentiCRISPRv2 vectors. Puromycin was added at day 2 (2 mg/ml). Knock-out efficiency was measured by western blotting at day 8-10. THP-1 cells were infected and analyzed as described previously. U87 cells were infected as previously described for HeLa cells. NONO KO 293FT cells were obtained by transfected transiently 293FT by 3 mg of pLentiCRISPRv2-NONO-gRNA#40 or 1.5 mg of pX458 with 1.5 mg gRNA-NONO#1. Twenty-four hour after, puromycin (2 mg/ml ; for pLentiCRISPRv2) or neomycin (10 mg/ml; for gRNA-NONO#1) were added. The day after, cells were suspended in fresh media, in presence of antibiotics selection, and plated by limiting dilution in 96 well plates in order to generate a monoclonal cell line. Twenty-four hour after, the media was replaced by fresh media without antibiotics selection. Following clonal expansion of 2 weeks, knock-out efficiency was measured by western blotting. The clone 1 was the clone 1B8 obtained from pLentiCRISPRv2-NONO-gRNA#40 and the clone 2 was the clone 1C3 obtained from gRNA-NONO#1.
IP-10 protein quantification IP-10 concentration was measured on pure or 10-fold dilutions (controls and HIV infection) or 10 to 100-fold dilutions (poly(I:C), R848, HT-DNA, cGAMP) of supernatants from infected DCs or MDMs. IP-10 concentration was measured using a Human IP-10 cytometric assay (BD) according to manufacturer's protocol. Data was acquired on a BD FACSVerse (BD) and analyzed in FCAP Array (BD).
IFN-b and IFN-l1 proteins quantifications
IFN-b and IFN-l1 concentration were measured on supernatants from infected or treated DCs or MDMs. IFN-b and IFN-l1 concentration were measured using a LEGENDplex Human Anti-Virus Response assay (BioLegend) according to manufacturer's protocol. Data were acquired on a BD FACSVerse (BD) and analyzed with LEGENDplex Software (BioLegend).
Quantitative bioassay for IFNs Supernatants were assayed for IFN activity using the HL116 cell line as previously described (Lahaye et al., 2013) .
HIV Real-time PCR
Real-time PCR analysis was performed as previously described (Lahaye et al., 2013) . Each sample was measured in triplicate for all primers (primer sequences are listed in Table S6 ). For beta-globin, primers were bglobin-f and bglobin-r. For HIV-2 Late RT, primers were hiv2-3 0 U3-fwd and hiv2-psi-rev. For HIV-2 2LTR, primers were hiv2-3 0 U3-rev and hiv2-R-fwd. For HIV-2 integrated DNA two rounds of amplification were performed. For the first round, primers were alu1 and hiv2-r. For the second round, 1 ml of first-round reaction was used as template, and primers were hiv2-f2 and hiv2-r2. For HIV-1 Late RT, primers were hiv1-3 0 U3-fwd and hiv1-psi-rev2. For HIV-1 2LTR JNCT, primers were Junct4 -fwd and Junct2-rev. For HIV-1 integrated DNA two rounds of amplification were performed. For the first round, primers were alu1 and hiv1-psi-rev2. For the second round, 1 ml of first-round reaction was used as template, and primers were hiv1-f2 and hiv1-r2. Cycling conditions were 1x 95 C 5 0 ; 35x 95 C -10,'' 65 C -20,'' 72 C -30 .'' Relative concentrations of Late RT, 2LTR and integrated viral DNA were calculated relative to beta-globin using the DCt method.
Gene expression quantification
Four days after lentiviral vector transduction of cDC2 or MDDCs, total RNA was extracted from 50 000 cells using Nucleospin RNA II kit (Macherey-Nagel). cDNA was synthesized with random hexamer from 0.1mg total RNA using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). Real-time qPCR was performed using SYBR Green I Master (Roche) . Expression level of mRNA was calculated with the standard curve method. The primer sequences are listed in Table S5 . Twenty-four hours (MDDCs) or forty-eight hours (MDMs) after treatment or infection from healthy donors versus NONO depleted patient's cells, or from lentiviral vector transducted cells, total RNA was extracted from 0.25 million of cells using Nucleospin RNA II kit (Macherey-Nagel). cDNA was synthesized with random hexamer from 0.1mg total RNA using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). Real-time qPCR was performed using SYBR Green I Master (Roche) . Expression level of mRNA was calculated with the standard curve method. The primer sequences are listed in Table S6 . The RNA left-over extracts were used for Microarray Data Analysis.
Western Blotting 0.5 to 2 million cells were lysed in 100 mL of RIPA buffer (50mM Tris HCl, 150mM NaCl, 0.1% SDS, 0.5% DOC, 1% NP-40, Protease inhibitor (Roche; 1187358001)). Lysis was performed on ice for 30 minutes. Lysates were cleared by centrifugation at 8000 g for 8 minutes at 4 C, and 20 ml of Laemmli 6X (12% SDS, 30% Glycerol, 0.375M Tris-HCl pH6.8, 30% 2-mercaptoehtanol, 1% bromophenol blue) was added and samples were boiled at 95 C for 15min. Virus supernatants were filtered at 0.45 mm, centrifuged at 16000 g for 1 h 30 min at 4 C. Virus pellets were lysed in 20 ml of RIPA buffer and 4 ml of Laemmli 6X was added and samples were boiled at 95 C for 15 min. Cellular and viral protein lysates were resolved on Criterion or 4%-20% Biorad precast SDS-PAGE gels and transferred on PVDF membrane. Membranes were saturated and proteins were blotted with antibodies (listed in KEY RESOURCES TABLE) in 5% non-fat dry milk, PBS, 0.1% Tween buffer. In the case of P-IRF3 or P-Sting analysis, one million of MDDCs were harvested at 16 h after infection or 12 h after cGAMP treatment, and were lysed in 50 mL of RIPA buffer complemented with 1x EDTA-free protease inhibitors cocktail (Roche), 50mM NaF and 1mM sodium orthovanadate. Lysis was performed on ice for 30 minutes. Lysates were cleared by centrifugation at 8000 g for 8 minutes at 4 C, and 10ml of Laemmli 6X was added and samples were boiled at 95 C for 15min. After migration and PVDF membrane transfer, membranes were saturated and proteins were blotted with antibodies (listed in KEY RESOURCES TABLE) in 2,5% BSA, TBS (Tris-buffered saline), 0.1% Tween filtrated buffer. ECL signal was recorded on the ChemiDoc-XRS or ChemiDoc Touch Biorad Imager. Data was analyzed and quantified with the Image Lab software (Biorad).
Cytoplasmic and nuclear fractionation
MDDCs were harvested at 24 h after infection (in presence or not of Raltegravir (RAL, 20mM) or of Azidothymidine (AZT, 25 mM)) or 16 h after cGAMP treatment. One million cells were washed once with room temperature PBS, gently pelleted and resuspended in 400 ml of cold cytoplasmic lysis buffer (CL buffer: 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 1 mM sodium orthovanadate, 50 mM NaF, complemented with 1x EDTA-free protease inhibitor cocktail (Roche)). Cells in cold CL buffer were immediately pelleted at 4 C (300 g, 4 min), the supernatant was discarded, 40 ml CL was added, and buffer and cells were gently resuspended by slow pipetting and soft flicking and left on ice for 15 min. Two and a half microliters of 10% NP-40 was added and cells were lysed by gentle flicking. Nuclei were pelleted at 15,700g for 5 min at 4 C. Forty microliters of supernatant were harvested and saved as the cytoplasmic fraction, and remaining liquid was discarded. Forty microliters of cold nuclear lysis buffer (NL buffer: 420 mM NaCl, 20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, 1 mM sodium orthovanadate, 50 mM NaF, complemented with 1x EDTA-free protease inhibitor cocktail (Roche)). Nuclei were resuspended by vigorous flicking and incubated on ice for 15 min, with occasional flicking. Nuclei were vortexed for 10 s and sonicated for 10 min in a 4 C bath sonicator (30 sec on, 30 sec off). The nuclear lysate was cleared by centrifugation at 15,700g for 5 min at 4 C, and the resulting supernatant was saved as the nuclear extract. Western blot Laemmli 6X loading buffer was added (8ml) to the cytoplasmic and nuclear extracts, and the samples were heated at 70 C for 15 min. Fourteen microliters of each sample was run on a Criterion SDS-PAGE gel (Biorad) and transferred to PVDF membrane (Biorad). Membranes were saturated and proteins were blotted with antibodies (listed in KEY RESOURCES TABLE) in 5% non-fat dry milk, PBS, 0.1% Tween buffer. ECL signal was recorded on the ChemiDoc-XRS or ChemiDoc Touch Biorad Imager. Data was analyzed and quantified with the Image Lab software (Biorad).
Recombinant protein expression/purification
Protein-expression vectors were transformed in E. Coli BL21 Star (DE3) (Thermo Fisher Scientific) for pDest His CypA, pDest His GST CA HIV-2 NTD (ROD9 strain, human codon optimized), pDest His ZZ CA HIV-1 NTD (NL4-3 strain), pDest His GST CA HIV-1 full length (NL4-3 strain) and in E. Coli Rosetta 2 (Novagen) for pET Duet NONO. Bacteria were plated on Ampicillin 0.1 mg/ml and Chloramphenicol 34 mg/ml. Single colonies were expanded in 2YT media with Ampicillin and Chloramphenicol 34 mg/ml at 37 C overnight. Precultures were diluted to OD600 0.05 and expanded up to OD600 0.5. For pET Duet NONO, the flasks are removed from the incubator and cooled in the cold room for 15 minutes before inducing the protein expression with IPTG 0.5 mM O/N at 25 C. For the other protein-expressions, protein expression was induced with IPTG 1 mM O/N at 25 C. Cells were washed in PBS and frozen. Bacteria were lysed for 1 hour at 4 C on a rotating wheel in PBS supplemented with 150 mM NaCl, 1 mg/ml lysozyme (Sigma), 10 mM MgCl2, 100 mg/ml DNase I (Roche), 0.5% Triton X-100, 15 mM imidazole and protease inhibitors (EDTA-free Complete cocktail, Roche). Lysates were clarified by centrifugation for 30 min at 75600 g and 4 C. His-tagged proteins were bound to Protino Ni-NTA agarose gel (Macherey-Nagel) for 1 hour at 4 C on a rotating wheel. Beads were centrifuged for 10 min at 470 g and 4 C, washed two times in PBS supplemented with 350 mM NaCl, and 1 time in 50 mM Tris-HCl pH 8. Beads were packed in columns (Machery-Nagel), and proteins were eluted in 50 mM Tris-HCl pH 8 with 250 mM imidazole. Proteins were quantified using a Bradford assay (Bio-Rad) and BSA standards (Pierce). His-ZZ-CA HIV-1 NTD, His-GST-CA HIV-1 full length, His-GST-CA HIV-2 NTD, His-CypA and NONO proteins were dialyzed overnight at 4 C against PBS and concentrated using Amicon Ultra-4 10K filter units. Integrity and purity of each protein was analyzed by SDS-PAGE followed by Coomassie dye staining (LabSafe GEL Blue).
Microscale Thermophoresis analysis
Fresh affinity-purified recombinant His-ZZ-CA HIV-1 NTD, His-GST-CA HIV-1 full length, His-GST-CA HIV-2 NTD, His-CypA and NONO proteins concentrations were determined with NanoDrop 2000 (Thermo Scientific). His-CypA and NONO were further labeled with the Monolith NT Protein Labeling Kit BLUE according to the recommendations of the manufacturer (NanoTemper Technologies). MST analyses were performed as previously described (Lahaye et al., 2013) . Capsids were 2-fold diluted sixteen times in PBS-Tween 0.05% and a one-to-one volume of His-CypA or NONO were added to a constant concentration of 500mM final. All measures were performed at 20 C, Laser power at 10% and LED power adjusted between 20 and 50% depending on the labeling intensity. All measures were performed in two or three locations per capillary, and measures were repeated independently three times. Kd values were calculated in the NTAnalysis software (NanoTemper technologies).
Yeast Two Hybrids Screen
Yeast two-hybrid screening was performed by Hybrigenics Services, S.A.S., Paris, France (https://www.hybrigenics-services.com). The coding sequence for HIV-2 capsid (aa 1-230) was PCR-amplified and cloned into pB27 and pB66 as a C-terminal fusion to LexA (LexA-HIV-2-Capsid) and the Gal4 DNA-binding domain (Gal4-HIV-2-Capsid), respectively. The constructs were checked by sequencing the entire insert and used as a bait to screen a random-primed Human Leukocyte/Activated Mononuclear Cells cDNA library constructed. For the LexA-HIV-2-Capsid bait construct, 123 million clones (12-fold the complexity of the library) were screened using a mating approach with YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, mata) and L40DGal4 (mata) yeast strains. 2 His+ colonies were selected on a medium lacking tryptophan, leucine and histidine. For the Gal4-HIV-2-Capsid bait construct, 80 million clones (8-fold the complexity of the library) were screened using the same mating approach with YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, mata) and CG1945 (mata) yeast strains. 112 His+ colonies were selected on a medium lacking tryptophan, leucine and histidine. The prey fragments of the positive clones were amplified by PCR and sequenced at their 5 0 and 3 0 junctions. The resulting sequences were used to identify the corresponding interacting proteins in the GenBank database (NCBI) using a fully automated procedure. A confidence score (PBS, for Predicted Biological Score) was attributed to each interaction as previously described (Formstecher et al., 2005) .
Yeast Two Hybrid Assays
The genotype of the Saccharomyces cerevisiae reporter strain L40 is MATatrp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ as previously reported (Janoueix-Lerosey et al., 1995) . Yeast strains were grown at 30 C in YPD medium (Fisher scientific). Insertion of NONO or Cyclophilin A in pGAD-GH and HIV-1, HIV-2, SIVmac239 and SIVsmm (clone BJ11.9) capsid in pLex9 were performed through gateway strategy. Deletion and Alanine scanning mutations were performed using the Q5 Site-Directed Mutagenesis Kit (NEB). Corresponding mutagenized sequences are listed in Table S2 . The yeast reporter strain L40 were co-transformed using the lithium acetate method. pLex9 constructs were used as Bait and pGAD-GH constructs were used as Prey as previously reported (Janoueix-Lerosey et al., 1995) . Double transformants were grown on plates containing DOB medium (MP Biomedicals) lacking Leu and Trp (control: L-W-) to select for the presence of both the bait and prey and deprived of His (selective: L-W-H-) to select for proteinprotein interaction. The plates were incubated at 30 C for 3 to 6 days. From 6 days growing yeasts on L-W-plate, a bit of a clone is diluted in 200ml sterile water and then diluted 1 to 10. Five ml drops were then plated on L-W-H-medium plates.
Immunoprecipitations 0.8 million of 293FT were plated in 6-well plates and transfected as previously described (Lahaye et al., 2013) with 1.5 mg of pcDNA3.1-Hygro (+) (Thermo Fisher Scientific) or pcDNA3.1-HA-NONO combined with pTRIP-CMV-eGFP-FLAG-cGAS E225A/ D227A. 24h later, supernatant was removed and changed with 2 mL of new media. 48h later transfection, supernatant was removed and 1ml of cold PBS was used to collect 2 wells/condition and transferred to an Eppendorf tube. Cells were then centrifuged at 240 g for 5 minutes. Cells pellet was resuspended with cold PBS and centrifuged again. Cells were lysed in 500ml of cold Ripa buffer (50 mM Tris HCl, 150 mM NaCl, 0.1% SDS, 0.5% DOC, 1% NP-40, Protease inhibitor (Roche; 1187358001)). Lysis was performed on ice for 30 minutes. Lysates were cleared by centrifugation at 8000 g for 8 minutes. Supernatant was transferred into new Eppendorf tube and 10% of the total volume was removed and collected as input cell lysate prior to adding anti-FLAG M2 Affinity gel (SIGMA#A-2220) or Protein G Mag Sepharose(TM) GE Healthcare beads coupled with HA antibodies. For Flag immunoprecipitation, 40 ml per sample of anti-FLAG M2 Affinity gel were washed three times with 1ml of complemented RIPA buffer and resuspended in 100ml of RIPA buffer. 100 ml of anti-FLAG M2 Affinity gel were added to 450 ml of lysates and incubated at 18 rpm constant wheel rotation at 4 C for 4h. For HA immunoprecipitation, 8ml per sample of Protein G Mag Sepharose (TM) GE Healthcare beads were washed twice with 1ml of complemented RIPA buffer and resuspended in 500 ml of RIPA buffer and 1 ml of HA antibody was added and incubated at 18 rpm constant wheel rotation at 4 C for 1 hour. Coupled HA-beads were washed twice with 1 mL of complemented RIPA buffer and resuspended in 100 ml of RIPA buffer. 100 ml of HA-beads were added to 450 ml of lysates and incubated at 18 rpm constant wheel rotation at 4 C for 4h. Immunoprecipitates were washed twice with 1 mL of RIPA buffer and twice with 1 mL of TN buffer (150 mM, Tris HCl pH 7.4, 20 mM NaCl, 0.01% NP40). Resulting 30 ml immunoprecipitates were complemented with 30 ml of 2x Laemmli Buffer and incubated at 95 C for 20 minutes. Fifteen ml of input cell lysate and of immunoprecipitates were loaded and analyzed by western blot as described previously. For the experiments with Benzonase treatment, lysates were cleared and transferred into fresh Eppendorf tubes. Two microliters of Benzonase (Sigma -E1014-25KU, final concentration 1.1U/ml) were added (or water for control) and incubated at 18 rpm constant wheel rotation at 4 C for 30min. Following this incubation, 10% of the total volume was removed and collected as input cell lysate prior to adding anti-FLAG M2 Affinity gel and processed as described above. As control, plasmid DNA were treated in 100ml of RIPA buffer by 0,45 ml of Benzonase (1.1U/ml), incubated at 18 rpm constant wheel rotation at 4 C for 4h30 (corresponding to the duration of the immunoprecipitation), migrated in 1% UltraPure Agarose gel (Thermo Fisher Scientific) in TAE buffer containing SYBR Safe (Thermo Fisher Scientific) and GelGreen (Biotium) Nucleic acid stain, and revealed with a ChemiDoc Touch Imager (BioRad). Data was analyzed and quantified with the Image Lab software (BioRad).
Immunofluorescence 0.1 million of MDDCs were infected or not as described above with HIV-2 (multiplicity of infection around 30) in presence of Raltegravir (RAL, 20 mM) in 96 well plate U-bottom and incubated for 16hr. Cells were then washed 2 times in 200 ml of DC media and resuspended in 50 ml of DC media. The 50 ml of cells were added 15 for 30 min at 37 C on coverslip coated with poly-L-lysine (0.1% in water; SIGMA 8920). Cells were fixed on the coverslip by adding 1ml 1xPHEM-3% PFA buffer (warm to 37 C), without removing media for 5 min at 37 C and 10 min at room temperature (2xPHEM buffer: for 500 ml, 18.14 g PIPES, 6.5 g HEPES, 3.8 g EGTA, 0.99 g MgSO4, pH to 7.0 with 10M KOH). Coverslips were washed 2 times with PBS (GIBCO), and incubated with 500 ml of fresh PBS-Glycine buffer (375 mg Glycine in 50 mL of water) for 10 min at room temperature. Coverslips were washed 2 times in 1x PHEM buffer and incubated with 500 ml of 0,1% Triton in 1x PHEM buffer for 10 min at room temperature. After two wash in PBS, coverslips were incubated with 500 ml of PBS, 0.2% BSA (Euromedex) for 20 min at room temperature. For NONO visualization, coverslips were incubated with primary antibodies (or isotype controls) diluted in PBS-BSA-10% goat serum for 3 hour at room temperature in the dark (mouse IgG2a a -NONO at 1:500) against NONO or mouse IgG2a isotype control (at 1:1000). Coverslip were washed 4 times with PBS-BSA and incubated with secondary diluted in PBS-BSA (goat a-mouse-Alexa 555 at 1:1000) for 1 hour in the dark. Coverslips were washed 5 times every 3 minutes with PBS-BSA, 1 time with PBS, rinsed in water and mounted on slide with Fluoromount-G (SouthernBiotech 0100-01) and dried for 30min at 37 C. NONO localization images were acquired on an inverted SP8 confocal microscope (Leica). For NONO and cGAS visualization in transduced MDDCs, cells were fixed with PHEM-3% PFA and quenched with glycine. Coverslips were blocked and permeabilized with 1 mL of PBS, 0.2% BSA, 0.05% Saponin (SIGMA from quillaja bark) for 30 minutes at RT. Coverslips were incubated with primary antibodies (or isotype controls) diluted in PBS-BSA-Saponine-10% goat serum for 20 hours at room temperature in the dark: mouse monoclonal a-NONO at 1:500 (Milipore) or mouse IgG1 isotype control at 1:500, and rabbit monoclonal antibody a-cGAS at 1:200 (D1D3G; CST -Lot #1, concentration: 17mg/ml) or Normal Rabbit IgG Isotype control (Thermo Fischer Scientific). Coverslip were washed 4 times every 3 minutes with PBS-BSA and incubated with secondary diluted in PBS-BSA (goat a-mouse-Alexa 488 at 1:1000 and goat a-rabbit-Alexa 647 at 1:1000) for 1 hour in the dark. Coverslips were washed 5 times every 3 minutes with PBS-BSA, 1 time with PBS, rinsed in water and mounted on slide with Fluoromount-G (SouthernBiotech 0100-01) and dried for 30 min at 37 C. NONO and cGAS localization images were acquired on an inverted SP8 confocal microscope (Leica). For CA localization by Proteinase K treatment, just after the cells fixation, coverslips were washed 2 times D-PBS and Proteinase K treatment (Proteinase K Solution (20 mg/mL), RNA grade (FisherScientific)) was done with 500 ml of Proteinase K diluted at 1/1000 in D-PBS for 5 min at room temperature (if no treatment coverslips were incubated in D-PBS alone). Coverslips were washed 2 times with D-PBS, 1 time with PHEM 1x and incubated with 500 ml 1xPHEM-3%PFA buffer for 5 min at room temperature, in order to block completely Proteinase K activity. Coverslips were washed 2 times with PBS and incubated with 500 ml of fresh PBS-Glycine buffer for 10 min at room temperature. After two wash in PBS, coverslips were incubated with 500 ml of PBS, 0.2% BSA for 20 min at room temperature. Coverslips were incubated with primary antibodies (or isotype controls) diluted in PBS-BSA-10% goat serum for 3 hour at room temperature in the dark (mouse AG3.0 (at 1:500) against GAG/CA, mouse IgG1 isotype (at 1:500)). Coverslip were washed 4 times with PBS-BSA and incubated with secondary diluted in PBS-BSA (goat antimouse-Ig1-Alexa 647 (1/1000)) for 1 hour in the dark. Coverslips were washed 5 times with PBS-BSA, 1 time with PBS, rinsed in water and mounted on slide with Fluoromount-G (SouthernBiotech 0100-01) and dried for 30min at 37 C. Capsid localization images were acquired on an inverted SP8 confocal microscope (Leica). For CA localization by PLA reaction, cells were fixed with PHEM-3%PFA and quenched with glycine. Cells were permeabilized with PBS, 0.2% BSA, 0.05% Saponin. Coverslips were processed according to PLA protocol using Duolink In Situ Orange Starter Kit Mouse/Mouse (Sigma) with a combination of a-mouse AG3.0 (at 1:500) and a-mouse 183-H12-5C (at 1:500). Capsid localization images were acquired on an inverted SP8 confocal microscope (Leica).
cGAS-associated HIV-DNA Immunoprecipitation MDDC cells, control or depleted of NONO were infected with HIV-2 virus for 16hr, cross-linked in medium containing 1% formaldehyde for 8 min at RT, quenched with freshly prepared 0.25 M glycine for 5min at RT and washed thrice with ice-cold PBS. Cells were lysed in buffer containing 50 mM HEPES (pH 7.5), 140 mM NaCl, 1 mM EDTA pH 8.0, 10% glycerol, 0.25% (v/v) Triton X-100 and 0.75% (v/v) NP-40, then nuclei were pelleted at 400 g, washed in buffer containing 10 mM Tris, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and lysed in nuclei lysis buffer containing 10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.5% N-lauroysarcosine, 0.1% Na-Deoxycholate. Lysates were sonicated on Bioruptor Pico device (Diagenode) to obtain fragments ranging from 150 to 600 bp, and then centrifuged at 10,000 g for 10 minutes at 4 C to remove debris. All buffers were complemented with Protease inhibitor cocktail (Roche).
Immunoprecipitation was performed by overnight rotation of lysates with Protein A Dynabeads (Thermo Fisher) coupled to antibodies against c-GAS (D1D3G, Cell Signaling) or unspecific IgG (abcam, ab171870), considering 3 millions of cells and 3.4 mg antibodies per IP, in 400uL of nuclei lysis buffer complemented with of 5% of BSA. Lysates were washed with low salt washing buffer (140 mM NaCl) (5 times), high salt washing buffer (500 mM NaCl) (2 times), LiCl washing buffer (250 mM LiCl) (2 times), and TE buffer (1 time). Wash buffers were based on RIPA buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 140 mM NaCl, 1% (v/v) Triton X-100, 0.1% (v/v) SDS and 0.1% sodium deoxycholate).
DNA was eluted from beads in 1% SDS, 50 mM NaHCO3 by shacking 2 hours at 37 C in the presence of 10 mg/mL RNaseA (Thermo Fischer). Samples were decrosslinked overnight at 65 C in the presence of 0.2 mg/ml proteinase K and DNA was purified using MinElute kit (QIAGEN). Enrichments were analyzed by qPCR for HIV-2 Late RT using primers hiv2-3 0 U3-fwd and hiv2-psirev (primer sequences are listed in Table S6 ).
Image processing and analysis
Images were processed and analyzed with ImageJ Fiji. For NONO Nuclear and cGAS Nuclear/Cytoplasmic quantification, a mask of all nuclei was obtained by thresholding the DAPI channel image and individual nucleus were detected using ''analyze particles'' function. For each nucleus, we first measured the mean cGAS and NONO intensity inside the nucleus. Next, the region of interest corresponding to each nucleus was enlarged by a 1.2 factor to compute the mean cytoplasmic cGAS intensity at the periphery. A cytoplasmic mask was obtained by thresholding the cGAS signal to avoid to take ''out of cytoplasm'' areas in the enlarge nuclei region of interest. For nuclear PLA capsid foci quantification, 3D masks of nuclei were first obtained using an auto-threshold function (intermodes method) and 3D object counter plugin was used to identify and separate all nuclei. Then, PLA spots were detected using 3D maxima finder function (from the 3D ImageJ Suite plugins) and counted inside each nucleus.
Electron microscopy
Electron microscopy observations were produced by transfection of 293FT cells in 6-well plates on coverslips with 3 mg DNA and 8 mL TransIT-293 (Mirus Bio) per well; for HIV-1 or HIV-1 CA variants. One night after transfection, media was removed, cells were washed out once and fresh media was added. One day after transfection, cells were then fixed in 2% glutaraldehyde on cell media for 20 min at 37 C. Cells were fixed in 2% glutaraldehyde in 0.1 M cacoldylate buffer, pH 7.4 for 1 hour, post fixed for 1 hour with 2% buffered osmium tetroxide, dehydrated in a graded series of ethanol solution, and then embedded in epoxy resin. Images were acquired with a digital camera Quemesa (SIS) mounted on a Tecnai 12 transmission electron microscope (FEI Company) operated at 80kV.
Immuno-electron microscopy
Uninfected MDDCs, MDDCs infected with HIV-2 or HIV-2 DJ+DGag for 16 hours in presence of Raltegravir (20 mM) or MDMs infected with replicative competent virus NL(AD8) for 7 days were fixed and processed for cryomicrotomy as described previously (Berre et al., 2013) . For MDDCs, cells from two donors were combined in each experiment. Immunoelectron microscopy was performed by the Tokuyasu method (Slot and Geuze, 2007) . Protein A coupled to gold particles of 10 or 15 nm diameter was purchased from G. Posthuma (University Medical Center, Utrecht, the Netherlands). Electron microscopy chemicals were from Electron Microscopy Sciences (Pennsylvania). Antibodies used were: mouse monoclonal a-gp120 ADP (Aalto Bio Reagents at 1:50) and rabbit polyclonal a-NONO (Sigma at 1:50). Images were acquired with a digital camera Quemesa (SIS) mounted on a Tecnai 12 transmission electron microscope (FEI Company) operated at 80kV.
Microarray Data and Bio-informatics methods
The data was obtained with Affymetrix Human Gene 2.1 ST arrays. Micro-array analyses were processed with R (version 3.0.0) using packages from Bioconductor. The quality control was performed using ArrayQualityMetrics (version 3.34.0) package without detecting any outlier among the experiment. Data was normalized using the Robust Multi-Array Average algorithm from the Oligo package (version 1.42.0). Annotation of the probes was done using the annotation updated file (2015/04/15) for Human Gene 2.1 ST Arrays from the Affymetrix website (version 3.34.9). Differential gene-expression analysis was performed with Limma (version 8.7.0). either including HIV-1+Vpx (6 samples per condition) or cGAMP (3 samples per condition). A probe-level selection based on fold change > 2 and p < 5% for HIV-2 versus non-infected controls in WT cells was applied (n = 127 and n = 165 probes, respectively). In case of multiple probes per gene, the probe with highest fold-change was selected (n = 123 and n = 161 genes, respectively). ISGs previously identified were highlighted (n = 331 genes) (Schoggins et al., 2011) . Raw data has been deposited to NCBI GEO (GEO: GSE109554). Software and Algorithms were described in DATA AND SOFTWARE AVAILABILITY section.
Expression and purification of human cGAS
The cDNA encoding full-length human cGAS was purchased from Open Biosystems and cloned into a modified pET-28(a) vector with an N-terminal His6-SUMO tag. The His6-SUMO-hcGAS fusion protein was expressed in E. coli strain BL21(DE3) induced with 0.4 mM isopropyl b-D-1-thiogalactopyranoside (IPTG). After 20 hours induction at 15 C, the cells were harvested by centrifugation at 4000 rpm. The pellets were resuspended in lysis buffer (50 mM Tris, 500 mM NaCl, at pH 8.0) and lysed by sonication. After centrifugation at 16,000 rpm for 30 min, the supernatant containing the target protein was loaded onto a Ni 2+ -NTA agarose (QIAGEN) column equilibrated with the lysis buffer. The column was subsequently washed with a buffer containing 50 mM Tris, 500 mM NaCl and 25 mM imidazole at pH 8.0. The target protein was eluted with an elution buffer containing 20 mM Tris, 500 mM NaCl, and 250 mM imidazole at pH 7.5. The purified His6-SUMO-hcGAS was cleaved with SUMO protease overnight at 4 C. The His 6 -SUMO tag was removed using a Ni 2+ -NTA agarose column. Human cGAS in the flow through was concentrated and purified by gel filtration chromatography using a HiLoad 16/60 Superdex 200 column (GE Healthcare) eluted with a buffer containing 20 mM Tris and 500 mM NaCl at pH 7.5. The purified hcGAS was concentrated, frozen in liquid nitrogen, and stored at À80 C.
Fluorescence based in vitro cGAS activity
The assay was adapted from a previous study (Andreeva et al., 2017) . Briefly, 0.5 mM of purified cGAS were mixed with 9 ng/ml (experiment #1), 7.5 ng/ml (experiment #2) or 7 ng/ml (experiment #3) of either Human Native Nucleosomes (Millipore), nuclesomal DNA purified from Human Native Nucleosomes (Millipore), or a 11 kb plasmid DNA in presence of 40 mM UltraPure Tris HCl, pH 7.5 (Thermo Fisher) and 100 mM of NaCl (Thermo Fisher) in a final volume of 100 ml. Nucleosomal DNA was extracted from 50 ml out of 100 ml Human Native Nucleosomes (Millipore) with a Nucleospin Gel and PCR Clean-Up kit (Macherey-Nagel) following manufacturer instructions. DNA was eluted in 20ml of elution buffer. The reaction mix was dispensed in a Black 96w plate in PS Nunc F96 MicroWell (Thermo Fisher) and the plate was preincubated at 37 C for 10 minutes prior to starting the reaction in a FLUOstar OPTIMA (BMG Labtech). 100 ml of a reaction starting mix composed by 5 mM MgCl2 (Thermo Fisher), 500mM of GTP (Sigma) and 50 mM of fluorescent ATP [fATP -2-Aminopurine riboside-5 0 -O-triphosphate (2-NH 2 -PuTP)] (Biolog), preincubated at 37 C for 10 minutes, were added to each reaction well. Fluorescence acquisition was immediately started after adding the reaction starting mix on a FLUOstar OPTIMA (BMG Labtech) (excitation: 305nm, emission: 360, Gain 1400, 2 minutes acquisition interval, temperature 37 C). Data was analyzed and exported to Excel with MARS Data Analysis Software (BMG Labtech).
Host phylogenetic and evolutionary analyses
Phylogenetics and evolutionary analyses were performed as previously described (Abdul et al., 2018; Chougui et al., 2018) . Orthologous sequences of the primate NONO gene were retrieved using UCSC Blat and NCBI Blastn with the human sequence as the query. Sequences annotated as non-coding (XR/NR identification) were discarded. We confirmed the conserved synteny of the selected orthologous genes using UCSC and NCBI. In total, the orthologous sequences of 20 primate species were included and codon-aligned using PRANK v150803 with the default parameter -F (http://wasabiapp.org/software/prank/). We used GARD from HYPHY v2.220170615beta to assess for recombination with a cut-off at p < 0.05 (https://veg.github.io/hyphy-site/). PhyML v3.2 was used for the phylogenetic reconstructions with a HKY+G+I model and 1,000 bootstrap replicates for statistical support of the branches (http://www.atgc-montpellier.fr/phyml/).
Marks of positive selection were assessed using maximum-likelihood tests performed by three softwares: HYPHY, PAML v4.9e Codeml, and Bio++ v2.2.0. In HYPHY, we used the BUSTED method to detect gene-wide evidence of positive selection within a codon alignment. In PAML Codeml and Bio++, we used the NONO gene tree inferred with PhyML as input. The gene-coding sequence alignments were fit to models that disallow (M1, two classes of u (u = dN/dS): u < 1 and u = 1) or allow (M2, three classes: u < 1, u = 1, and u > 1) for positive selection. The likelihood of the models was compared using a chi-square test to derive p values. To detect (episodic) site-specific positive selection, we used MEME and FUBAR from HYPHY, the BEB (Bayes Empirical Bayes) analysis from the M2 model in PAML Codeml, and the Bayesian Posterior Probabilities (PP) from the M2 model in Bio++. Software and Algorithms were described in DATA AND SOFTWARE AVAILABILITY section.
Virus phylogenetic analyses
The nucleotide sequences of the gag gene from primate lentiviruses were retrieved from the Los Alamos HIV sequence database curated alignments on June, 24th 2018. Three alignments were recovered: (i) with ''HIV-1/SIVcpz'' sequences, (ii) with ''HIV-2/ SIVsmm'' sequences, and (iii) with all SIV and some HIV sequences (named ''Other SIV (includes HIV1 and HIV2 sequences)'' in the database). Each alignment was then ungapped, translated and aligned using MAFFT v7.310 (https://mafft.cbrc.jp/alignment/ software/). In the obtained amino-acid alignments, positions which had gaps in more than 10% of the sequences were trimmed using SeqMagick v0.6.1 (https://fhcrc.github.io/seqmagick/). The NONO-binding motifs were subsequently isolated and separated according to the lentiviral lineage/group. A sequence logo was then produced for each motif and each lineage/group of viruses using WebLogo v3.6.0 (http://weblogo.threeplusone.com/).
To reconstruct the lentiviral phylogeny of gag, we used the nucleotide sequences from the third primate lentiviral alignment (total, 202 HIV and SIV sequences) and we re-aligned them using PRANK with the default parameter -F (http://wasabiapp. org/software/prank/). We discarded the following sequences that were poorly aligned: SMM.US.04.M934.JX860421, H2U.FR.96.12034.AY530889 and SAB.SN.x.SAB1.U04005. We used GARD to assess for recombination (cut-off, p < 0.05). We reconstructed the phylogeny using PhyML v3.2 with a GTR+G+I model and aLRT for branch support. The clade of SIVcol sequences was used as outgroup. Branches were collapsed using FigTreev1.4.3 (http://tree.bio.ed.ac.uk/software/figtree/). Software and Algorithms were described in DATA AND SOFTWARE AVAILABILITY section.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact value of n, dispersion and precision measures (as mean ± SEM) and statistical significance are reported in the Figures and Figure Legends . In figures asterisks denote statistical significance *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001, ''ns'' = not significant. Comparisons between any 3 or more groups were analyzed by analysis of variance (ANOVA) or as indicated otherwise in figure legends. Statistical analysis was performed in GraphPad PRISM 7 (Graph Pad Software).
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data files of the Affymetrix Human Gene 2.1 ST arrays reported in this paper is NCBI GEO: GSE109554. The microarray data analysis and bio-informatics methods are described in the METHOD DETAILS. Figure S1 . NONO Directly Binds to HIV-1 and HIV-2 Capsid Proteins, Related to Figure 1 (A) Percentage and number of interactions identified in a yeast two-hybrid screen using the HIV-2 CA as bait and a random-primed Human Leukocyte/Activated Mononuclear Cells cDNA library. The letters indicate the score obtained for each interaction. (B) Interactions between full length capsids (CA) of HIV-1 or HIV-2 or a negative control protein Rab1aDQ with NONO and CypA, measured by yeast two-hybrid (n = 3, one representative experiment is shown). (C) Interactions between the N-terminal domains (NTD) of the capsid (CA) proteins of HIV-1 or HIV-2 or a negative control protein Rab1aDQ with NONO and CypA, measured by yeast two-hybrid and using dilutions to estimation the strength of the interactions (n = 3, one representative experiment is shown). (D) Coomassie analysis of the recombinant proteins CypA, NONO, HIV-1 WT or HIV-2 WT CA NTD proteins purified after expression in bacteria with the indicated plasmids (n = 3, one representative experiment is shown). (E) Interaction between NONO and recombinant NTD or full length of HIV-1 capsids, measured by microscale thermophoresis (n = 3). Figure S3 . NONO Is Essential for Immune Activation after HIV Infection in Dendritic Cells and Macrophages, Related to Figure 2 
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